Blood Cancer Journal
SCIE-ISI SCOPUS (2011-2025)
2044-5385
2044-5385
Mỹ
Cơ quản chủ quản: Springer Nature , Nature Publishing Group
Lĩnh vực:
OncologyHematology
Các bài báo tiêu biểu
CAR-T cell therapy: current limitations and potential strategies
Tập 11 Số 4
AbstractChimeric antigen receptor (CAR)-T cell therapy is a revolutionary new
pillar in cancer treatment. Although treatment with CAR-T cells has produced
remarkable clinical responses with certain subsets of B cell leukemia or
lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid
tumors and hematological malignancies. Barriers to effective CAR-T cell therapy
include sev...
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
Tập 6 Số 8 - Trang e458-e458
AbstractThe adoptive transfer of CD19-specific chimeric antigen receptor
engineered T cells (CAR T cells) resulted in encouraging clinical trials in
indolent B-cell malignancies. However, they also show the limitations of this
fascinating technology: CAR T cells can lead to even life-threatening off-tumor,
on-target side effects if CAR T cells crossreact with healthy tissues. Here, we
describe a n...
IL-10 induces the development of immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma
Tập 5 Số 7 - Trang e328-e328
AbstractThe biological role of monocytes and macrophages in B-cell non-Hodgkin
lymphoma (NHL) is not fully understood. We have previously reported that
monocytes from patients with B-cell NHL have an immunosuppressive
CD14+HLA-DRlow/− phenotype that correlates with a poor prognosis. However, the
underlying mechanism by which CD14+HLA-DRlow/− monocytes develop in lymphoma is
unknown. In the present...
EZH2 alterations in follicular lymphoma: biological and clinical correlations
Tập 7 Số 4 - Trang e555-e555
AbstractThe histone methyltransferase EZH2 has an essential role in the
development of follicular lymphoma (FL). Recurrent gain-of-function mutations
inEZH2have been described in 25% of FL patients and induce aberrant methylation
of histone H3 lysine 27 (H3K27). We evaluated the role ofEZH2genomic gains in FL
biology. Using RNA sequencing, Sanger sequencing and SNP-arrays, the mutation
status, cop...
Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia
Tập 8 Số 6
AbstractTherapy for acute myeloid leukemia (AML) involves intense cytotoxic
treatment and yet approximately 70% of AML are refractory to initial therapy or
eventually relapse. This is at least partially driven by the chemo-resistant
nature of the leukemic stem cells (LSCs) that sustain the disease, and therefore
novel anti-LSC therapies could decrease relapses and improve survival. We
performed in...
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
Tập 8 Số 11
AbstractWe collected 1500 patients with myeloproliferative neoplasms (MPN) and
arterial or venous thrombosis (935/565), pooling three independent cohorts
previously reported. Long-term treatment with antiplatelet drugs or vitamin
K-antagonists (VKA) was given to 1391 (92.7%) patients; 975 (65%) patients
received hydroxyurea (HU). We recorded 348 recurrences (venous in 142 cases)
over 6075 patient-...
Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors
Tập 6 Số 9 - Trang e469-e469
AbstractThe vast majority of patients with acute myeloid leukemia (AML) achieve
complete remission (CR) after standard induction chemotherapy. However, the
majority subsequently relapse and die of the disease. A leukemia stem cell (LSC)
paradigm has been invoked to explain this failure of CR to reliably translate
into cure. Indeed, LSCs are highly enriched in CD34+CD38− leukemic cells that
exhibit...
Myelofibrosis Treatment Algorithm 2018
Tập 8 Số 8
AbstractTwo novel prognostic systems for primary myelofibrosis (PMF) were
recently unveiled: GIPSS (genetically inspired prognostic scoring system) and
MIPSS70 (mutation-enhanced international prognostic scoring system for
transplant-age patients). GIPSS is based exclusively on genetic markers:
mutations and karyotype. MIPSS70 includes mutations and clinical risk factors.
In its most recent adapta...